Modifiable Risk Factors for Alzheimer's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2019 Jul 12

PMID 31293412

Citations 107

Authors

George A Edwards Iii

Nazaret Gamez

Gabriel Escobedo Jr

Olivia Calderon

Ines Moreno-Gonzalez

Affiliations

Soon will be listed here.

Abstract

Since first described in the early 1900s, Alzheimer's disease (AD) has risen exponentially in prevalence and concern. Research still drives to understand the etiology and pathogenesis of this disease and what risk factors can attribute to AD. With a majority of AD cases being of sporadic origin, the increasing exponential growth of an aged population and a lack of treatment, it is imperative to discover an easy accessible preventative method for AD. Some risk factors can increase the propensity of AD such as aging, sex, and genetics. Moreover, there are also modifiable risk factors-in terms of treatable medical conditions and lifestyle choices-that play a role in developing AD. These risk factors have their own biological mechanisms that may contribute to AD etiology and pathological consequences. In this review article, we will discuss modifiable risk factors and discuss the current literature of how each of these factors interplay into AD development and progression and if strategically analyzed and treated, could aid in protection against this neurodegenerative disease.

Citing Articles

Editorial: Animal models of Alzheimer's disease and other dementias: past, present, and future.

Moreno-Gonzalez I, Garcia-Martin J, Marongiu R Front Aging Neurosci. 2025; 16():1539837.

PMID: 39834617 PMC: 11743453. DOI: 10.3389/fnagi.2024.1539837.

Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges.

Safiri S, Ghaffari Jolfayi A, Fazlollahi A, Morsali S, Sarkesh A, Daei Sorkhabi A Front Med (Lausanne). 2024; 11:1474043.

PMID: 39736972 PMC: 11682909. DOI: 10.3389/fmed.2024.1474043.

Non-enzymatic posttranslational protein modifications in protein aggregation and neurodegenerative diseases.

Baldensperger T, Preissler M, Becker C RSC Chem Biol. 2024; 6(2):129-149.

PMID: 39722676 PMC: 11667106. DOI: 10.1039/d4cb00221k.

On the health effects of curcumin and its derivatives.

Ayub H, Islam M, Saeed M, Ahmad H, Al-Asmari F, Ramadan M Food Sci Nutr. 2024; 12(11):8623-8650.

PMID: 39620006 PMC: 11606848. DOI: 10.1002/fsn3.4469.

Evaluating disparity of subjective cognitive decline between male veterans and non-veterans in the United States using propensity score matching estimation: A behavioral risk factor surveillance system survey cross-sectional study.

Ifebirinachi C, Park M, Kim S PLoS One. 2024; 19(9):e0310102.

PMID: 39269972 PMC: 11398683. DOI: 10.1371/journal.pone.0310102.

References

Reijs B, Vos S, Soininen H, Lotjonen J, Koikkalainen J, Pikkarainen M . Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. J Alzheimers Dis. 2017; 60(4):1387-1395. DOI: 10.3233/JAD-170039. View

Berhanu W, Yasar F, Hansmann U . In silico cross seeding of Aβ and amylin fibril-like oligomers. ACS Chem Neurosci. 2013; 4(11):1488-500. PMC: 3837374. DOI: 10.1021/cn400141x. View

Ju Y, McLeland J, Toedebusch C, Xiong C, Fagan A, Duntley S . Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013; 70(5):587-93. PMC: 3676720. DOI: 10.1001/jamaneurol.2013.2334. View

Soto C . Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003; 4(1):49-60. DOI: 10.1038/nrn1007. View

Um H, Kang E, Leem Y, Cho I, Yang C, Chae K . Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int J Mol Med. 2008; 22(4):529-39. View

Shen Y, Joachimiak A, Rosner M, Tang W . Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006; 443(7113):870-4. PMC: 3366509. DOI: 10.1038/nature05143. View

Hebert L, Weuve J, Scherr P, Evans D . Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013; 80(19):1778-83. PMC: 3719424. DOI: 10.1212/WNL.0b013e31828726f5. View

Abner E, Nelson P, Jicha G, Cooper G, Fardo D, Schmitt F . Tobacco Smoking and Dementia in a Kentucky Cohort: A Competing Risk Analysis. J Alzheimers Dis. 2019; 68(2):625-633. PMC: 6915304. DOI: 10.3233/JAD-181119. View

Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la Torre R, Martinez-Gonzalez M . Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial. JAMA Intern Med. 2015; 175(7):1094-1103. DOI: 10.1001/jamainternmed.2015.1668. View

10.

Zemlan F, Rosenberg W, Luebbe P, Campbell T, Dean G, Weiner N . Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem. 1999; 72(2):741-50. DOI: 10.1046/j.1471-4159.1999.0720741.x. View

11.

Moreno-Gonzalez I, Edwards Iii G, Salvadores N, Shahnawaz M, Diaz-Espinoza R, Soto C . Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding. Mol Psychiatry. 2017; 22(9):1327-1334. PMC: 5495631. DOI: 10.1038/mp.2016.230. View

12.

Garcia-Alloza M, Gregory J, Kuchibhotla K, Fine S, Wei Y, Ayata C . Cerebrovascular lesions induce transient β-amyloid deposition. Brain. 2011; 134(Pt 12):3697-707. PMC: 3235567. DOI: 10.1093/brain/awr300. View

13.

Horvath A, Szucs A, Barcs G, Noebels J, Kamondi A . Epileptic Seizures in Alzheimer Disease: A Review. Alzheimer Dis Assoc Disord. 2016; 30(2):186-92. DOI: 10.1097/WAD.0000000000000134. View

14.

Loughrey D, Lavecchia S, Brennan S, Lawlor B, Kelly M . The Impact of the Mediterranean Diet on the Cognitive Functioning of Healthy Older Adults: A Systematic Review and Meta-Analysis. Adv Nutr. 2017; 8(4):571-586. PMC: 5502874. DOI: 10.3945/an.117.015495. View

15.

Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L . Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer. 2007; 121(6):1296-305. DOI: 10.1002/ijc.22763. View

16.

Richards M, Jarvis M, Thompson N, Wadsworth M . Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Public Health. 2003; 93(6):994-8. PMC: 1447882. DOI: 10.2105/ajph.93.6.994. View

17.

Roberson E, Halabisky B, Yoo J, Yao J, Chin J, Yan F . Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011; 31(2):700-11. PMC: 3325794. DOI: 10.1523/JNEUROSCI.4152-10.2011. View

18.

Dhouafli Z, Cuanalo-Contreras K, Hayouni E, Mays C, Soto C, Moreno-Gonzalez I . Inhibition of protein misfolding and aggregation by natural phenolic compounds. Cell Mol Life Sci. 2018; 75(19):3521-3538. PMC: 11105286. DOI: 10.1007/s00018-018-2872-2. View

19.

Beach T, Wilson J, Sue L, Newell A, Poston M, Cisneros R . Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 2006; 113(1):13-21. DOI: 10.1007/s00401-006-0136-y. View

20.

Vemuri P, Lesnick T, Przybelski S, Knopman D, Lowe V, Graff-Radford J . Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol. 2017; 82(5):706-718. PMC: 5696029. DOI: 10.1002/ana.25071. View